Bayer
BAY2599023 (DTX201)
Hemophilia A
Countdown
71days
Phase 2 readout · Sep 15, 2026
What's at stake
Phase 2 trial results for BAY2599023 (DTX201) in Hemophilia A are due Sep 15, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 13h ago
“CT.gov NCT03588299: Phase 2 trial, sponsor Bayer, drug BAY2599023 (DTX201). Primary completion date 2026-09-15 (estimated).”